Mergers and Acquisitions

Jan 24, 2025

The 2025 J.P. Morgan Healthcare Conference ignited a new era of M&A activity, marking the industry’s largest consolidation wave in recent years.  The M&A rebound in the healthcare sector has been years in the making, as pharma giants like J&J, GSK, and others face looming patent cliffs, threaten...

Jan 17, 2024

From January 8th to 11th, 2024, the 42nd Annual J.P. Morgan Healthcare Conference (JPM24) took center stage in San Francisco, CA, USA. Spanning four dynamic days, this conference saw the active participation of prominent figures from major pharmaceutical, biotechnology, Medtech, HealthTech entities, and emerging fa...

Jul 23, 2019

Generic Lyrica: FDA nods to first generic alternatives to Pfizer’s Lyrica The U.S. FDA has approved the first generic substitute of Pfizer’s Lyrica (pregabalin) in its commitment to facilitate the access of high-quality generic medicines at lower prices to patients. Lyrica is the second most selling drug of the...

Jun 13, 2019

Telegenomics Company Genome Medical nets USD 23 M Genome Medical, a telegenomics company, having expertise in delivering genome-based medicine has raised USD 23 Million in series B funding.  The proceeds will be used by the company to accelerate the development of its technology and medical services to supp...

Apr 20, 2017

Prescription drug supply shortages fuel price hikes, new research shows According to research published by the New England Journal of Medicine and reported by the Wall Street Journal, shortages of prescription drug supplies in the U.S. in recent years resulted in price increases for some drugs. In 2014 and 2015, a ...

Mar 30, 2017

Mylan closing Illinois plant, cutting 90 jobs as part of slim-down after Meda buyout Mylan has been in the midst of cutting about 3,500 jobs to decrease costs and refocus after its $7 billion buyout last year of Meda Pharmaceuticals. About 90 of those cuts will come with the closure of a plant in Illinois.The drugma...

Dec 08, 2016

With $496M CNS sale, Novartis joins other Pharma companies casting off tired meds The latest Big Pharma to join the asset-sale party is Novartis, which is in talks to offload some of its older central nervous system (CNS) drugs, including Ritalin for attention deficit disorder and Exelon patch for Alzheimer’s. The p...